DMAA
Drugs Made In America Acquisition Corp.
$10.66
+0.01 (+0.05%)
At close · Jul 10
Market Cap
$258.79M
Shares
24,276,913
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.66
Open$10.65
Day$10.65–10.66
52W$10.17–10.66
Avg vol 30d45K
Short int83K · 0.3% float · 2.3d
Short vol80%
DataFeb 2025–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+0%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+3%
trailing
YTD return
+3%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.34% of float · ▲ +8.4% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
39 holders — near 1-yr high, broad support
Squeeze score
43
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
2%
annualized · 1-yr
Max drawdown
0%
past year
ATR
0.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.34% of float · ▲ +8.4% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
39 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $11 · 100%
52-wk high $11
vs 200-day avg +2%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAA
this stock
Drugs Made In America Acquisition Corp.
|
$258.79M | +2.8% | — | — | 0.3% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | +0.0% | — | 100.2 | — |
|
XXI
Twenty One Capital, Inc.
|
$3.43B | -39.8% | — | — | 0.7% |
|
CCXI
Churchill Capital Corp XI
|
$866.14M | — | — | — | 0.9% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$643.37M | +2.0% | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAA | +0.1% | +0.5% | +2.5% | +0.1% | +2.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.3% | -3.6% | -6.6% | -1.0% | -8.0% |
Key facts
CIK
2028614
CUSIP
G2847J104
13F (30d)
1 filings
1 filers